Literature DB >> 19624802

Usefulness of measuring reticulocyte hemoglobin equivalent in the management of haemodialysis patients with iron deficiency.

N Miwa1, T Akiba, N Kimata, Y Hamaguchi, Y Arakawa, T Tamura, K Nitta, K Tsuchiya.   

Abstract

The evaluation of iron status in dialysis patients provides information essential to the planning of adequate recombinant human erythropoietin treatment. The cellular iron status of the patients can be determined from the recently available measurement of reticulocyte hemoglobin equivalent (RET-He). RET-He is measured on the basis of automated fluorescent flow cytometry which in the reticulocyte channel, using a polymethine dye, also measures the mean value of the forward light scatter intensity of mature red blood cells and reticulocytes. These values equate with reticulocyte hemoglobin content. In this study, to clarify the accuracy of RET-He in diagnosing iron deficiency in dialysis patients, we initially compared RET-He with such iron parameters as serum ferritin levels, transferrin saturation and content of reticulocyte hemoglobin (CHr) which has been established as indicators of functional iron deficiency. Secondly, we investigated the changes in RET-He during iron supplementation for iron-deficient patients to determine whether this marker is a prospective and reliable indicator of iron sufficiency. The participants in this study were 217 haemodialysis patients. Iron deficiency was defined as havsing a transferrin saturation (TSAT) < 20% or serum ferritin < 100 ng/ml. Conventional parameters of red blood cells and RET-He were measured by on a XE-2100 automated blood cell counter (Sysmex). CHr was measured on an ADVIA120 autoanalyser (Siemens). RET-He mean value was 32.4 pg and good correlation (r = 0.858) between RET-He and CHr is obtained in dialysis patients. Receiver operating characteristic curve analysis revealed, values of the area was 0.776 and at a cutoff value of 33.0 pg, a sensitivity of 74.3% and a specificity of 64.9%, were achieved. Iron supplements given to the patients with low TSAT or ferritin, RET-He responded within 2 weeks, and this seemed to be a potential advantage of using RET-He in the estimation of iron status. RET-He is a new parameter, equivalent value to CHr, and is easily measurable on the widely spread and popular blood cell counter and is a sensitive and specific marker of iron status in dialysis patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19624802     DOI: 10.1111/j.1751-553X.2009.01179.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  11 in total

1.  Using the hemoglobin content of reticulocytes (RET-He) to evaluate anemia in patients with cancer.

Authors:  Ellinor I B Peerschke; Melissa S Pessin; Peter Maslak
Journal:  Am J Clin Pathol       Date:  2014-10       Impact factor: 2.493

2.  Reticulocyte Hemoglobin Content During the First Month of Life in Critically Ill Very Low Birth Weight Neonates Differs From Term Infants, Children, and Adults.

Authors:  Raeda T Al-Ghananim; Demet Nalbant; Robert L Schmidt; Gretchen A Cress; M Bridget Zimmerman; John A Widness
Journal:  J Clin Lab Anal       Date:  2015-05-13       Impact factor: 2.352

3.  Reticulocyte hemoglobin equivalent as a potential marker for diagnosis of iron deficiency.

Authors:  Yasumichi Toki; Katsuya Ikuta; Yoshie Kawahara; Noriyasu Niizeki; Masayuki Kon; Motoki Enomoto; Yuko Tada; Mayumi Hatayama; Masayo Yamamoto; Satoshi Ito; Motohiro Shindo; Yoko Kikuchi; Mitsutaka Inoue; Kazuya Sato; Mikihiro Fujiya; Toshikatsu Okumura
Journal:  Int J Hematol       Date:  2017-03-15       Impact factor: 2.490

4.  Renal functional and structural integrity in infants with iron deficiency anemia: relation to oxidative stress and response to iron therapy.

Authors:  Mohamed S El-Shimi; Rania A El-Farrash; Eman A Ismail; Ibrahim A El-Safty; A El-Safty; Ahmed S Nada; Omayma A El-Gamel; Yomna M Salem; Sara M Shoukry
Journal:  Pediatr Nephrol       Date:  2015-05-16       Impact factor: 3.714

5.  Evaluation of Iron Status by Reticulocyte Haemoglobin Content (Chr) in Chronic Kidney Disease Patients on Haemodialysis and Erythropoietin.

Authors:  Piumanthi Karunarathne; Chandima Kulathilake; Indira Wijesiriwardena; Anura Hewageegana; Arjuna Marasinghe
Journal:  Indian J Hematol Blood Transfus       Date:  2021-07-03       Impact factor: 0.900

6.  Comparison of reticulocyte hemoglobin equivalent with traditional markers of iron and erythropoiesis in pediatric dialysis.

Authors:  Sarka Davidkova; Timothy D Prestidge; Peter W Reed; Tonya Kara; William Wong; Chanel Prestidge
Journal:  Pediatr Nephrol       Date:  2015-12-14       Impact factor: 3.714

7.  Reticulocyte hemoglobin equivalent to detect thalassemia and thalassemic hemoglobin variants.

Authors:  Å A Sudmann; A Piehler; P Urdal
Journal:  Int J Lab Hematol       Date:  2012-07-06       Impact factor: 2.877

8.  Delta-He: a novel marker of inflammation predicting mortality and ESA response in peritoneal dialysis patients.

Authors:  Kristin Danielson; Soheir Beshara; Abdul Rashid Qureshi; Olof Heimbürger; Bengt Lindholm; Magnus Hansson; Britta Hylander; Guna Germanis; Peter Stenvinkel; Peter Barany
Journal:  Clin Kidney J       Date:  2014-05-14

9.  Serum hepcidin levels and reticulocyte hemoglobin concentrations as indicators of the iron status of peritoneal dialysis patients.

Authors:  Aya Eguchi; Takahiro Mochizuki; Misao Tsukada; Koji Kataoka; Yukio Hamaguchi; Shinichiro Oguni; Kosaku Nitta; Ken Tsuchiya
Journal:  Int J Nephrol       Date:  2012-11-01

Review 10.  Biomarkers of hypochromia: the contemporary assessment of iron status and erythropoiesis.

Authors:  Eloísa Urrechaga; Luís Borque; Jesús F Escanero
Journal:  Biomed Res Int       Date:  2013-02-28       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.